The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

Kepler Capital analyst Nicolas Pauillac maintained a Buy rating on MedinCell SA (MEDCL – Research Report) on February 26 and set a price ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45 th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live webcast and ...

Medincell has signed a strategic co-development and licensing agreement with AbbVie to develop next-generation long-acting injectable therapies. The partnership will jointly develop and market six ...

As European markets navigate a landscape marked by cautious optimism amid U.S. trade policy developments and geopolitical efforts, investors are increasingly focused on companies with strong growth ...

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

Medincell (Paris:MEDCL): This press release is not being made in and copies of it may not be distributed or sent, directly or indirectly, into the United States, Australia, South Africa, Canada or ...

Christophe Douat, CEO, and Richard Malamut, CMO, will present Medincell’s corporate overview at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 9:50am ET. Live ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...